Is the price fair?
What PTGX's price assumes
Protagonist Therapeutics, Inc. trades at 149× earnings against 32.4× for the median Biotechnology name, more expensive than its own group.
149
Trailing P/E · Biotechnology median 32.4 · 4.59× the median: the market pays up for this one
- Price / sales
- 100
Price / sales · as of 2026-Q1
- Free cash flow yield
- 1.8%
Free cash flow yield · Biotechnology median 2.5%
- Growth the price implies
- +19%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / book2026-Q1
- 11.3
- Healthcare median P/E362 names
- 31.5
- Biotechnology median P/E158 names
- 32.4
- Free cash flow, trailing twelve months
- $131M
- Market capitalisation
- $7.26B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.